Shire Plc (SHPG)

179.20
7.05 4.10
Prev Close 172.15
Open 176.60
Day Low/High 175.71 / 181.22
52 Wk Low/High 123.73 / 182.47
Volume 5.32M
Avg Volume 1.63M
Exchange
Shares Outstanding 300.99M
Market Cap 54.82B
EPS 14.30
Div & Yield 1.06 (0.59%)
Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

5 Toxic Stocks to Avoid

5 Toxic Stocks to Avoid

Here's a look at five 'toxic stocks' to sell.

Why Shire, Great Plains, GE Are Waving Red Flags

Why Shire, Great Plains, GE Are Waving Red Flags

The charts of these and two other big stocks are flashing warning signs at investors.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents

Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents

U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

Actelion Soars as Johnson & Johnson 'Makes Takeover Proposal'

Actelion Soars as Johnson & Johnson 'Makes Takeover Proposal'

The Swiss biotech was last year reported to be a target of Shire.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Stocks Slip in Uncertain Start to November Amid Election Uncertainty

Stocks Slip in Uncertain Start to November Amid Election Uncertainty

Stocks slip on Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

Stocks Suffer Bad Start to November as Election Uncertainty Overwhelms

Stocks Suffer Bad Start to November as Election Uncertainty Overwhelms

Wall Street suffered a dismal start to the month on Tuesday as conflicting polls bred uncertainty over the upcoming presidential election.

Stocks Extend Losses Amid Election Uncertainty, Crude Falls

Stocks Extend Losses Amid Election Uncertainty, Crude Falls

Stocks extend losses by mid-afternoon Tuesday in a weaker start to November as uncertainty over the upcoming presidential election weighs on Wall Street.

European Stock Markets Fall as Bond Selloff Hits Dividend Yielders Across the Board

European Stock Markets Fall as Bond Selloff Hits Dividend Yielders Across the Board

The German DAX leads the way as all major European indices close in the red on Tuesday.

Week Ahead: Fed Meeting, Jobs Report Paint Clearer Picture for Rate Hike Chances

Week Ahead: Fed Meeting, Jobs Report Paint Clearer Picture for Rate Hike Chances

The Federal Reserve will again convene in the coming week to discuss monetary policy, but investors will instead focus on what it may mean for a rate hike in December.

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.

Supernus Offers Super Small-Cap Potential

Supernus Offers Super Small-Cap Potential

Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.

Baxter Needs a Growth Injection From Management

Baxter Needs a Growth Injection From Management

Baxter reports its third-quarter earnings Tuesday.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

4 Biotechs Set to Provide a Shot in the Arm

4 Biotechs Set to Provide a Shot in the Arm

Each company has approaching catalysts.

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

9 Stocks Smart Investors Put Their Money in Last Quarter

9 Stocks Smart Investors Put Their Money in Last Quarter

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

Utilities Need to Get Their Act Together

If they're underperforming, they're typically a precursor to a market correction.

Radius Health, Subject of Takeover Talk, Rises Again

Radius Health, Subject of Takeover Talk, Rises Again

The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.